Use of cannabinoids in the treatment of epilepsy

Patent metadata

Field	Value
Publication number	US-10111840-B2
Application number	US-201514881969-A
Country	US
Kind code	B2
Filing date	Oct 13, 2015
Priority date	Oct 14, 2014
Publication date	Oct 30, 2018
Grant date	Oct 30, 2018

Abstract

The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

First claim

The invention claimed is:

1. A method of treating atonic seizures in a patient suffering from Dravet syndrome or Lennox-Gastaut syndrome, comprising administering cannabidiol (CBD) to the subject in need thereof, wherein the purity of the CBD is at least 98% (w/w) and comprises not more than 0.15% (w/w) Δ9-tetrahydrocannabinol, and wherein the dose of the CBD is about 20 mg/kg/day.

2. The method according to claim 1 , wherein the patient is suffering from Dravet Syndrome.

3. The method according to claim 1 , wherein patient is suffering from Lennox-Gastaut Syndrome.

4. The method according to claim 1 , wherein the CBD is administered in combination with one or more concomitant anti-epileptic drugs (AED) to the subject in need thereof at a recommended therapeutic dose.

5. The method according to claim 4 , wherein the one or more AED is selected from the group consisting of: clobazam; clonazepam, levetiracetam; topiramate; stiripentol; phenobarbital; lacsamide; valproic acid; zonisamide; perampanel; and fosphenytoin.

6. The method according to claim 4 , wherein the number of different anti-epileptic drugs that are administered in combination with the CBD to the subject in need thereof is reduced.

7. The method according to claim 4 , wherein the recommended therapeutic dose of the one or more anti-epileptic drugs that are administered in combination with the CBD to the subject in need thereof is reduced from the recommended therapeutic dose without CBD.

8. The method of claim 1 , wherein the CBD is administered as a composition comprising cannabidiol (CBD), a solvent, a co-solvent, a sweetener, and a flavouring to the subject in need thereof.

9. The method according to claim 8 , wherein the solvent is sesame oil.

10. The method according to claim 8 , wherein the co-solvent is ethanol.

11. The method according to claim 8 , wherein the sweetener is sucralose.

12. The method according to claim 8 , wherein the flavouring is strawberry flavour.

13. The method according to claim 8 , wherein the CBD is present at a concentration of between 25 mg/ml and 100 mg/ml.

14. The method according to claim 8 , wherein the composition comprises cannabidiol (CBD) at a concentration of between 25 to 100 mg/ml, ethanol as the co-solvent at a concentration of 79 mg/ml, sucralose as the sweetener at a concentration of 0.5 mg/ml, strawberry flavouring as the flavouring at a concentration of 0.2 mg/ml and sesame oil as the solvent q.s. to 1.0 ml.

Assignees

• Gw Pharma Ltd

Inventors

• Guy Geoffrey
• Wright Stephen
• Mead Alice
• Devinsky Orrin

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P25/08

  Antiepileptics; Anticonvulsants · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• A61K36/185

  Magnoliopsida (dicotyledons) · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title